Fig. 4From: G6PD maintains the VSMC synthetic phenotype and accelerates vascular neointimal hyperplasia by inhibiting the VDAC1–Bax-mediated mitochondrial apoptosis pathwayBoth pharmacological inhibition and knockdown of G6PD abolish PDGF-BB-induced VSMC apoptosis inhibition and survival. A Western blot analysis of caspase-9, cleaved caspase-9, caspase-7, cleaved caspase-7, PARP, cleaved PARP, and Bcl-2 in VSMCs. n = 3. B Cell apoptosis was evaluated by PE-conjugated Annexin V/7-AAD staining and quantified by flow cytometry. n = 3. C The viability of VSMCs was assessed by a CCK8 assay. n = 22. D Cell proliferation was measured by a cell counting experiment. n = 10. E Western blot analysis of caspase-9, cleaved caspase-9, caspase-7, cleaved caspase-7, PARP, cleaved PARP, and Bcl-2 in VSMCs. n = 3. F Cell apoptosis was evaluated by PE-conjugated Annexin V/7-AAD staining and quantified by flow cytometry. n = 3. G The viability of VSMCs was assessed by a CCK8 assay. n = 7. H Cell proliferation was measured by a cell counting experiment, n = 3. Statistical significance was determined using one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001Back to article page